Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial.

Details

Serval ID
serval:BIB_87880AB3A5A2
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial.
Journal
British journal of clinical pharmacology
Author(s)
Courlet P., Barbieux C., Sculier D., Wandeler G., Stoeckle M., Bernasconi E., Braun D., Vernazza P., Cavassini M., Marinosci A., Smit M., Günthard H.F., Schmid P., Limacher A., Guidi M., Alves Saldanha S., Decosterd L.A., Calmy A.
ISSN
1365-2125 (Electronic)
ISSN-L
0306-5251
Publication state
Published
Issued date
11/2021
Peer-reviewed
Oui
Volume
87
Number
11
Pages
4455-4460
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
This study aims to evaluate the association between dolutegravir (DTG) pharmacokinetic parameters and weight changes in treatment-experienced people with HIV (PWHIV) from the Simpl'HIV study newly switched to a dual DTG-based regimen. We used multivariable linear regressions to evaluate the association between DTG pharmacokinetic parameters at week 48 (derived using an established model) and weight change between week 0 and week 48. We adjusted our model for potential confounders including CD4 nadir, female sex, African origin, age, weight at week 0 and presence of a non-nucleoside reverse transcriptase inhibitor-based regimen before switch to DTG. The analysis included data from 39 PWHIV. An average significant weight gain of 2.4 kg was observed between baseline and week 48. DTG plasma exposure was not significantly associated with weight gain, even after adjusting for potential confounders (P = .9). We found no significant association between DTG pharmacokinetic parameters and weight gain amongst PWHIV newly switched to a DTG-based dual regimen.
Keywords
Anti-HIV Agents/adverse effects, Female, HIV Infections/drug therapy, HIV Integrase Inhibitors/adverse effects, Heterocyclic Compounds, 3-Ring/adverse effects, Humans, Oxazines, Piperazines, Pyridones/therapeutic use, Treatment Outcome, antiretroviral drugs, body weight, dolutegravir, pharmacokinetics, plasma concentrations
Pubmed
Web of science
Open Access
Yes
Create date
05/04/2021 10:35
Last modification date
22/07/2022 6:38
Usage data